Hardman Research: Turbo-charging into growth phase

RNS Number : 1027A

Chamberlin PLC

21 March 2017

 

Hardman Research: Turbo-charging into a new growth phase

Turbo-charging into a new growth phase: Chamberlin is refocussing.  Following its major contract win and with improved competitiveness, Chamberlin is further developing its product offering to the automobile turbocharger industry through expansion of its principle operational facilities. The risk/reward profile remains favourable and the shares are attractively valued both against its peer group and on a DCF basis.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/chamberlin-plc-documents/21.03.17-turbo-charging-into-a-new-growth-phase.pdf  

To contact us: Hardman & Co 11/12 Tokenhouse Yard  London EC2R 7AS

Contacts: Paul Singer [e-mail] Telephone: [phone] Follow us on Twitter @HardmanandCo

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 

END

 

 

NRALLFFSVIILFID